TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2308-2318

  Salzmann, Steffen ^a   Lang, Isabell ^a   Rosenthal, Alevtina ^a   Schäfer, Viktoria ^a   Weisenberger, Daniela ^a   Arana, José Antonio Carmona ^a   Trebing, Johannes ^a   Siegmund, Daniela ^a   Neumann, Manfred ^a   Wajant, Harald ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER APOPTOSIS; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ANTIGENS, CD40; BLOTTING, WESTERN; CD40 LIGAND; CELL LINE; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTORS;

EID: 84883401846     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202899     Document Type: Article

References (56)

1. Burkly, L. C., J. S. Michaelson, and T. S. Zheng. 2011. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol. Rev. 244: 99-114.
2. Winkles, J. A. 2008. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7: 411-425.
3. Meighan-Mantha, R. L., D. K. Hsu, Y. Guo, S. A. Brown, S. L. Feng, K. A. Peifley, G. F. Alberts, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, et al. 1999. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J. Biol. Chem. 274: 33166-33176.
4. Kawakita, T., K. Shiraki, Y. Yamanaka, Y. Yamaguchi, Y. Saitou, N. Enokimura, N. Yamamoto, H. Okano, K. Sugimoto, K. Murata, and T. Nakano. 2004. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem. Biophys. Res. Commun. 318: 726-733.
5. Willis, A. L., N. L. Tran, J. M. Chatigny, N. Charlton, H. Vu, S. A. Brown, M. A. Black, W. S. McDonough, S. P. Fortin, J. R. Niska, et al. 2008. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol. Cancer Res. 6: 725-734.
6. Jakubowski, A., C. Ambrose, M. Parr, J. M. Lincecum, M. Z. Wang, T. S. Zheng, B. Browning, J. S. Michaelson, M. Baetscher, B. Wang, et al. 2005. TWEAK induces liver progenitor cell proliferation. J. Clin. Invest. 115: 2330-2340.
7. Tirnitz-Parker, J. E., C. S. Viebahn, A. Jakubowski, B. R. Klopcic, J. K. Olynyk, G. C. Yeoh, and B. Knight. 2010. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 52: 291-302.
8. Dogra, C., H. Changotra, N. Wedhas, X. Qin, J. E. Wergedal, and A. Kumar. 2007. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21: 1857-1869.
9. Girgenrath, M., S. Weng, C. A. Kostek, B. Browning, M. Wang, S. A. Brown, J. A. Winkles, J. S. Michaelson, N. Allaire, P. Schneider, et al. 2006. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 25: 5826-5839.
10. Mittal, A., S. Bhatnagar, A. Kumar, E. Lach-Trifilieff, S. Wauters, H. Li, D. Y. Makonchuk, D. J. Glass, and A. Kumar. 2010. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. 188: 833-849.
11. Mittal, A., S. Bhatnagar, A. Kumar, P. K. Paul, S. Kuang, and A. Kumar. 2010. Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am. J. Pathol. 177: 1732-1742.
12. Ho, D. H., H. Vu, S. A. Brown, P. J. Donohue, H. N. Hanscom, and J. A. Winkles. 2004. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res. 64: 8968-8972.
13. Zhao, Z., L. C. Burkly, S. Campbell, N. Schwartz, A. Molano, A. Choudhury, R. A. Eisenberg, J. S. Michaelson, and C. Putterman. 2007. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J. Immunol. 179: 7949-7958.
14. Dohi, T., A. Borodovsky, P. Wu, J. R. Shearstone, R. Kawashima, L. Runkel, L. Rajman, X. Dong, M. L. Scott, J. S. Michaelson, et al. 2009. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 136: 912-923.
15. Haile, W. B., R. Echeverry, F. Wu, J. Guzman, J. An, J. Wu, and M. Yepes. 2010. Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience 171: 1256-1264.
16. Haile, W. B., R. Echeverry, J. Wu, and M. Yepes. 2010. The interaction between tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 promotes the recruitment of neutrophils into the ischemic brain. J. Cereb. Blood Flow Metab. 30: 1147-1156.
17. Hotta, K., M. Sho, I. Yamato, K. Shimada, H. Harada, T. Akahori, S. Nakamura, N. Konishi, H. Yagita, K. Nonomura, and Y. Nakajima. 2011. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int. 79: 179-188.
18. Zhang, X., J. A. Winkles, M. C. Gongora, R. Polavarapu, J. S. Michaelson, K. Hahm, L. Burkly, M. Friedman, X. J. Li, and M. Yepes. 2007. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J. Cereb. Blood Flow Metab. 27: 534-544.
19. Kamata, K., S. Kamijo, A. Nakajima, A. Koyanagi, H. Kurosawa, H. Yagita, and K. Okumura. 2006. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J. Immunol. 177: 6433-6439.
20. Perper, S. J., B. Browning, L. C. Burkly, S. Weng, C. Gao, K. Giza, L. Su, L. Tarilonte, T. Crowell, L. Rajman, et al. 2006. TWEAK is a novel arthritogenic mediator. J. Immunol. 177: 2610-2620.
21. Nakayama, M., K. Ishidoh, N. Kayagaki, Y. Kojima, N. Yamaguchi, H. Nakano, E. Kominami, K. Okumura, and H. Yagita. 2002. Multiple pathways of TWEAK-induced cell death. J. Immunol. 168: 734-743.
22. Schneider, P., R. Schwenzer, E. Haas, F. Mühlenbeck, G. Schubert, P. Scheurich, J. Tschopp, and H. Wajant. 1999. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur. J. Immunol. 29: 1785-1792.
23. Vince, J. E., D. Chau, B. Callus, W. W. Wong, C. J. Hawkins, P. Schneider, M. McKinlay, C. A. Benetatos, S. M. Condon, S. K. Chunduru, et al. 2008. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFα. J. Cell Biol. 182: 171-184.
24. Roos, C., A. Wicovsky, N. Mü ller, S. Salzmann, T. Rosenthal, H. Kalthoff, A. Trauzold, A. Seher, F. Henkler, C. Kneitz, and H. Wajant. 2010. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-κB pathway. J. Immunol. 185: 1593-1605.
25. Polek, T. C., M. Talpaz, B. G. Darnay, and T. Spivak-Kroizman. 2003. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J. Biol. Chem. 278: 32317-32323.
26. Wiley, S. R., L. Cassiano, T. Lofton, T. Davis-Smith, J. A. Winkles, V. Lindner, H. Liu, T. O. Daniel, C. A. Smith, and W. C. Fanslow. 2001. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15: 837-846.
27. Tran, N. L., W. S. McDonough, B. A. Savitch, S. P. Fortin, J. A. Winkles, M. Symons, M. Nakada, H. E. Cunliffe, G. Hostetter, D. B. Hoelzinger, et al. 2006. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-κB and correlate with poor patient outcome. Cancer Res. 66: 9535-9542.
28. Brown, S. A., C. M. Richards, H. N. Hanscom, S. L. Feng, and J. A.Winkles. 2003. The Fn14 cytoplasmic tail binds tumour-necrosis-factor- receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-κB activation. Biochem. J. 371: 395-403.
29. Razani, B., A. D. Reichardt, and G. Cheng. 2011. Non-canonical NF-κB signaling activation and regulation: principles and perspectives. Immunol. Rev. 244: 44-54.
30. O'Donnell, M. A., and A. T. Ting. 2011. RIP1 comes back to life as a cell death regulator in TNFR1 signaling. FEBS J. 278: 877-887.
31. Wajant, H., and P. Scheurich. 2011. TNFR1-induced activation of the classical NF-κB pathway. FEBS J. 278: 862-876.
32. Wicovsky, A., S. Salzmann, C. Roos, M. Ehrenschwender, T. Rosenthal, D. Siegmund, F. Henkler, F. Gohlke, C. Kneitz, and H. Wajant. 2009. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ. 16: 1445-1459.
33. Hess, S., and H. Engelmann. 1996. A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med. 183: 159-167.
34. Wyzgol, A., N. Müller, A. Fick, S. Munkel, G. U. Grigoleit, K. Pfizenmaier, and H. Wajant. 2009. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J. Immunol. 183: 1851-1861.
35. Boschert, V., A. Krippner-Heidenreich, M. Branschädel, J. Tepperink, A. Aird, and P. Scheurich. 2010. Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cell. Signal. 22: 1088-1096.
36. Fick, A., I. Lang, V. Schäfer, A. Seher, J. Trebing, D. Weisenberger, and H. Wajant. 2012. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J. Biol. Chem. 287: 484-495.
37. Lang, I., A. Fick, V. Schäfer, T. Giner, D. Siegmund, and H. Wajant. 2012. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts. J. Biol. Chem. 287: 24026-24042.
38. Elgueta, R., M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo, and R. J. Noelle. 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229: 152-172.
39. Henkler, F., E. Behrle, K. M. Dennehy, A. Wicovsky, N. Peters, C. Warnke, K. Pfizenmaier, and H. Wajant. 2005. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J. Cell Biol. 168: 1087-1098.
40. Siegel, R. M., J. R. Muppidi, M. Sarker, A. Lobito, M. Jen, D. Martin, S. E. Straus, and M. J. Lenardo. 2004. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J. Cell Biol. 167: 735-744.
41. Hassan, G. S., Y. Merhi, and W. Mourad. 2012. CD40 ligand: a neo-inflammatory molecule in vascular diseases. Immunobiology 217: 521-532.
42. Engel, D., T. Seijkens, M. Poggi, M. Sanati, L. Thevissen, L. Beckers, E. Wijnands, D. Lievens, and E. Lutgens. 2009. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Semin. Immunol. 21: 308-312.
43. Lynch, C. N., Y. C. Wang, J. K. Lund, Y. W. Chen, J. A. Leal, and S. R. Wiley. 1999. TWEAK induces angiogenesis and proliferation of endothelial cells. J. Biol. Chem. 274: 8455-8459.
44. Muñoz-García, B., J. Madrigal-Matute, J. A. Moreno, J. L. Martin-Ventura, O. López-Franco, C. Sastre, L. Ortega, L. C. Burkly, J. Egido, and L. M. Blanco-Colio. 2011. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc. Res. 89: 225-233.
45. Muñoz-García, B., J. A. Moreno, O. López-Franco, A. B. Sanz, J. L. Martín-Ventura, J. Blanco, A. Jakubowski, L. C. Burkly, A. Ortiz, J. Egido, and L. M. Blanco-Colio. 2009. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 29: 2061-2068.
46. -/- mice and inhibits macrophage lipid uptake in vitro. Arterioscler. Thromb. Vasc. Biol. 29: 2021-2027.
47. Filusch, A., T. Zelniker, C. Baumgärtner, S. Eschricht, N. Frey, H. A. Katus, and E. Chorianopoulos. 2011. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. Clin. Res. Cardiol. 100: 879-885.
48. Karadurmus, N., S. Tapan, M. Cakar, I. Naharci, T. Celik, I. Tasci, S. Sayin, T. Dogan, T. Turker, M. K. Erbil, and K. Saglam. 2012. Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension. Clin. Invest. Med. 35: E20-E26.
49. Martín-Ventura, J. L., J. S. Lindholt, J. A. Moreno, M. Vega de Céniga, O. Meilhac, J. B. Michel, J. Egido, and L. M. Blanco-Colio. 2011. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 214: 486-489.
50. Chorianopoulos, E., M. Rosenberg, C. Zugck, J. Wolf, H. A. Katus, and N. Frey. 2009. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur. J. Heart Fail. 11: 1050-1056.
51. Richter, B., K. Rychli, P. J. Hohensinner, R. Berger, D. Mörtl, S. Neuhold, G. Zorn, K. Huber, G. Maurer, J. Wojta, et al. 2010. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 213: 545-548.
52. Urbonaviciene, G., J. L. Martin-Ventura, J. S. Lindholt, S. Urbonavicius, J. A. Moreno, J. Egido, and L. M. Blanco-Colio. 2011. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis 219: 892-899.
53. Karmann, K., W. Min, W. C. Fanslow, and J. S. Pober. 1996. Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. J. Exp. Med. 184: 173-182.
54. + T cell-induced endothelial cell activation in vitro. Cell. Immunol. 190: 12-22.
55. Kotowicz, K., G. L. Dixon, N. J. Klein, M. J. Peters, and R. E. Callard. 2000. Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology 100: 441-448.
56. Maisch, T., B. Kropff, C. Sinzger, and M. Mach. 2002. Upregulation of CD40 expression on endothelial cells infected with human cytomegalovirus. J. Virol. 76: 12803-12812.